BMO Capital Markets Reiterates Market Perform Rating, $6 PT for ZIOPHARM Oncology

Loading...
Loading...
In a report published earlier today, BMO Capital Markets reiterated its Market Perform rating and $6.00 price target for ZIOPHARM Oncology, Inc.
ZIOP
. BMO Capital went on to say “While we are encouraged by progress toward broadening of palifosfamide development beyond soft tissue sarcoma (STS), we continue to believe that a high hurdle exists to demonstrate a statistically significant benefit in progression free survival (PFS). Certainly phase 2 PICASSO2 data is encouraging; however, patient numbers were small and confidence intervals were wide. We believe the DNA therapeutics platform in oncology and IL-12 gene activation therapy in melanoma specifically could drive significant value; however, safety of the oral gene activator, therapeutic index of the IL12 component and further detail on phase 2 design and regulatory path will be important to better assess the opportunity.” ZIOPHARM Oncology, Inc. closed yesterday at $5.89.
Posted In: Analyst ColorReiterationAnalyst RatingsBMO Capital Markets
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...